Search

Displaying results 6721 - 6730 of 7893 in total
  1. Drug

    PF-04856884

    go.drugbank.com/drugs/DB17550
    Investigational

    PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor.

  2. Drug

    Pucotenlimab

    go.drugbank.com/drugs/DB17552
    ApprovedInvestigational

    Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours.

  3. Drug

    Polyvalent antigen-KLH conjugate vaccine

    go.drugbank.com/drugs/DB17565
    Investigational

    Polyvalent antigen-KLH conjugate vaccine is a multivalent cancer vaccine comprised of the five tumor-associated antigens (TAAs) globo H, GM2 ganglioside, Tn-MUC1, TF, and sTn conjugated with the immunoadjuvant

  4. Drug

    Emprumapimod

    go.drugbank.com/drugs/DB17603
    Investigational

    Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.

  5. Drug

    Ammonium tetrathiomolybdate

    go.drugbank.com/drugs/DB17641
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    SerpinPC

    go.drugbank.com/drugs/DB17698
    Investigational

    SerpinPC is a mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for the treatment of hemophilia.[A258993]

  7. Drug

    Thalagen

    go.drugbank.com/drugs/DB17714
    Experimental

    Thalagen is a branded product developed by San Rocco Therapeutics. … It consists of autologous CD34-positive hematopoietic progenitor cells transduced with TNS9.3.55, a lentiviral vector encoding the normal human beta-globin gene.

  8. Drug

    MOD-5014

    go.drugbank.com/drugs/DB17715
    Investigational

    MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa.[A259088] It is being investigated for the treatment of hemophilia.[L46173]

  9. Drug

    NM3086

    go.drugbank.com/drugs/DB17719
    Experimental

    NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being developed by Novelmed Therapeutics Inc.[L46193]

  10. Drug

    OMS906

    go.drugbank.com/drugs/DB17722
    Investigational

    OMS906 is a humanized Igg4 monoclonal antibody against mannan-binding lectin-associated serine protease-3 (MASP-3) currently being developed by Omeros.